Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome by Sata, Masataka & Ikebe, Mitsuo
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
1996-12-15 
Functional analysis of the mutations in the human cardiac beta-
myosin that are responsible for familial hypertrophic 
cardiomyopathy. Implication for the clinical outcome 
Masataka Sata 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Physiology Commons 
Repository Citation 
Sata M, Ikebe M. (1996). Functional analysis of the mutations in the human cardiac beta-myosin that are 
responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. Open Access 
Articles. https://doi.org/10.1172/JCI119115. Retrieved from https://escholarship.umassmed.edu/
oapubs/1001 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 2866
 
M. Sata and M. Ikebe
 
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/96/12/2866/08 $2.00
Volume 98, Number 12, December 1996, 2866–2873
 
Functional Analysis of the Mutations in the Human Cardiac 
 
b
 
-Myosin that Are
Responsible for Familial Hypertrophic Cardiomyopathy
 
Implication for the Clinical Outcome
 
Masataka Sata and Mitsuo Ikebe
 
Department of Physiology, University of Massachusetts Medical Center, Worcester, Massachusetts 01655-0127
 
Abstract
 
More than 30 missense mutations in the 
 
b
 
-cardiac myosin
heavy chain gene have been shown to be responsible for fa-
milial hypertrophic cardiomyopathy. To clarify the effects
of these point mutations on myosin motor function, we ex-
pressed wild-type and mutant human 
 
b
 
-cardiac myosin
heavy chains in insect cells with human cardiac light chains.
The wild-type myosin was well purified with similar enzy-
matic and motor activities to those of the naturally isolated
 
V3 cardiac myosin. Arg
 
249
 
fi
 
Gln and Arg
 
453
 
fi
 
Cys mutations
resulted in decreased actin translocating activity (61 and
23% of the wild-type, respectively) with decreased intrinsic
ATPase activity. Arg
 
403
 
fi
 
Gln mutation greatly decreased
actin translocating activity (27% of wild type) with a 3.3-
fold increased dissociation constant for actin, while intrinsic
ATPase activity was unchanged. Val
 
606
 
fi
 
Met mutation only
mildly affected the actin translocating activity as well as
ATPase activity of myosin. The degree of deterioration by
each mutation was closely correlated with the prognosis of
the affected kindreds, indicating that myosin dysfunction
caused by the point mutations is responsible for the patho-
genesis of the disease. Structure/function relationship of
 
myosin is discussed. (
 
J. Clin. Invest. 
 
1996
 
. 
 
98:2866–2873.)
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Introduction
 
Familial hypertrophic cardiomyopathy (FHC)
 
1
 
 is an autosomal
dominant disease characterized by a hypertrophied left ventri-
cle in the absence of other causes of cardiac hypertrophy (1).
While FHC is one of the causes of sudden and unexpected car-
diac death, particularly in healthy young individuals, there is
no specific clinical feature which identifies the patients at risk
of sudden death (2). At the present time, 
 
.
 
 30 different mis-
sense mutations in the 
 
b
 
-cardiac myosin heavy chain (MHC)
gene, which alter only a single amino acid residue, have been
described (3–5). Phenotypic examinations of the genotypically
defined kindreds showed that certain 
 
b
 
-cardiac myosin heavy
chain gene mutations carry greater risk of morbidity than oth-
ers (6–9), demonstrating that mutations in 
 
b
 
-cardiac MHC
must be responsible for the pathogenesis of FHC. Since each
of the altered amino acids has been highly conserved during
evolution (6), it has been suggested that these residues are cru-
cial for myosin function. However, it remained to be clarified
how these myosin mutations affect myosin function, particu-
larly its motor activity, thus causing cardiac malfunction.
One of the problems for physiological and/or biochemical
studies of FHC is the difficulty of obtaining enough myosin sam-
ple from a patient’s heart. To avoid this difficulty, Cuda et al. ob-
tained biopsy samples from patient’s slow skeletal muscle fibers
which also express 
 
b
 
-MHC along with skeletal muscle myosin
and attempted to evaluate the effects of mutations on the
 
b
 
-myosin motor function (10). They selected 
 
b
 
-myosin from
the mixture of skeletal muscle myosin and 
 
b
 
-myosin using a
 
b
 
-MHC specific antibody and showed that 
 
b
 
-myosin from the
patients translocated actin filaments much slower than normal
control. However, their preparation is a mixture of the mutated
and nonmutated 
 
b
 
-myosins and it is postulated that the ratio of
the normal and mutant 
 
b
 
-myosins in patient’s heart would be
different from that in slow skeletal muscle fiber. Furthermore,
since the data represent the activity of 
 
b
 
-myosin of unknown
ratio of the normal and mutant myosins, it is difficult to quanti-
tatively evaluate the function of mutant 
 
b
 
-myosin. Obviously,
such an analysis can only be made with pure 
 
b
 
-myosin mutant.
On the other hand, Sweeney et al. expressed rat 
 
a
 
-cardiac
 
myosin in insect cells and reported that Arg
 
403
 
fi
 
Gln mutation
resulted in reduction of actin activated ATPase activity and
actin translocating activity (11). Problem is, however, only
 
b
 
-MHC but not 
 
a
 
-MHC is expressed in human adult left
ventricle (12) and V1 cardiac myosin isoform, homodimer of
 
a
 
-MHC, has three to fourfold higher activity than V3 isoform,
homodimer of 
 
b
 
-MHC, in both actin-translocating velocity
and actin-activated ATPase activity (13–16). Divergence be-
tween 
 
a
 
- and 
 
b
 
-MHCs clusters in functionally important re-
gions including ATP, actin, and light chain–binding sites (17).
Therefore, the effect of the point mutation on the rat 
 
a
 
-cardiac
myosin may be different from that on the human 
 
b
 
-myosin.
The purpose of this study is to express functionally active
recombinant human 
 
b
 
-myosin mutants found in the FHC pa-
tients and to analyze the effects of each mutation on the motor
activity. The active human 
 
b
 
-MHCs expressed with human
ventricular myosin light chains were successfully purified and
the motor and enzymatic activities of myosin mutants were de-
termined. Each 
 
b
 
-MHC mutant showed abnormal function ac-
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1. 
 
Abbreviations used in this paper:
 
 FHC, familial hypertrophic cardio-
myopathy; MHC, myosin heavy chain; HMM, heavy meromyosin;
LC1, light chain 1; LC2, light chain 2; S1, subfragment 1; S2, subfrag-
ment 2; RT-PCR, reverse transcriptase coupled polymerase chain re-
action.
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cording to the site and the type of the mutation. Interestingly,
the degree of deterioration by the mutation was well correlated
with the mortality rate among the affected kindreds supporting
the idea that the alteration of 
 
b
 
-myosin motor activity by muta-
tion is the critical factor for the prognosis of FHC patients.
 
Methods
 
Protein preparation. 
 
Cardiac V3 myosin was prepared from an au-
topsied human left ventricular muscle as described previously (14).
Cardiac heavy meromyosin (HMM) and myosin subfragment 1 (S1)
were prepared by 
 
a
 
-chymotrypsin digestion (18). Actin was prepared
from rabbit skeletal muscle acetone powder (19).
 
Construction of transfer vectors. 
 
Total RNA was prepared from
a left ventricular muscle obtained during autopsy of a 44-yr-old pa-
tient without clinical and pathological evidence of heart disease (20).
With two primers designed based upon the published sequence (21,
22), a truncated human 
 
b
 
-cardiac MHC cDNA (3414 bp) encoding
Met
 
1
 
-Asp
 
1138
 
 was obtained by reverse transcriptase-coupled PCR
(RT-PCR) (23), generating a stop codon at 3415 bp and flanking
 
XbaI sites on both ends (Fig. 1). The forward primer was 5
 
9
 
-CGC-
CTGGCTCTAGAATGGGAGATTCGGAGATG-3
 
9
 
, and the re-
verse primer was 5
 
9
 
-GCTCTCTAGACTAGTCTGAGCGCAGCT-
TCTCCAC-3
 
9
 
. This PCR product was digested with XbaI and
subcloned into pBluescript SK II (
 
1
 
) (Stratagene, La Jolla, CA). The
sequence of the obtained cDNA was confirmed to be identical to that
published previously by dideoxynucleotide termination method using
Sequenase 2.0 (United States Biochemical, Cleveland, OH). Four
point mutations, 746
 
G
 
fi
 
A
 
, 1208
 
G
 
fi
 
A
 
, 1357
 
C
 
fi
 
T
 
, and 1816
 
G
 
fi
 
A
 
 were intro-
duced into the 
 
b
 
-MHC cDNA individually using a transformer site
directed mutagenesis kit (Clontech Inc., Palo Alto, CA). These muta-
tions resulted in substitutions of Arg
 
249
 
 for Gln (Arg249Gln), Arg
 
403
 
for Gln (Arg403Gln), Arg
 
453
 
 for Cys (Arg453Cys), and Val
 
606
 
 for Met
(Val606Met), respectively, which have been shown to be responsible
for FHC (6). Wild and mutant human cardiac 
 
b
 
-MHC cDNAs thus
prepared were excised with XbaI digestion, and subcloned into a bac-
ulovirus transfer vector, pBlueBacM (Invitrogen, San Diego, CA) us-
ing an unique NheI site.
A full length cDNA encoding the human ventricular light chain 1
(LC1) (24) was a generous gift from Dr. Yazaki (University of Tokyo,
Tokyo, Japan). The cDNA was excised from a eukaryotic expression
Figure 1. Construction of the human b-MHC cDNA 
transfer vector. A detailed strategy for constructing 
the transfer vector is described in Methods. The first 
3414 bp of the 59-terminus of human b-MHC cDNA 
were synthesized by RT-PCR from human left ven-
tricular total RNA. The cDNA fragment is repre-
sented as a shaded box. ATG and TAG indicate initi-
ation and termination codons, respectively. The PCR 
product was excised with XbaI digestion and sub-
cloned into pBluescript SK II (1). After introduction 
of a missense mutation, the cDNA was excised with 
XbaI digestion and subcloned into a baculovirus 
transfer vector, pBlueBacM.
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vector, pDR540 (Pharmacia LKB Biotechnology Inc., Uppsala, Swe-
den), with BamHI digestion and subcloned into pBlueBacM using a
BamHI site. A full length cDNA encoding the human ventricular
light chain 2 (LC2) was obtained from human left ventricular total
RNA by RT-PCR with primers designed based upon the published
sequence (25), generating flanking XbaI sites on both ends. The for-
ward primer was 5
 
9
 
-CGCATCTAGAATGGCACCTAAGAAAG-
CAAAG-3
 
9
 
. The reverse primer was 5
 
9
 
-GACTTCTAGACTAGTC-
CTTCTCTTCTCCG-3
 
9
 
. This PCR product was digested with XbaI
and subcloned into pBlueBacM using a NheI site.
 
Purification of the expressed human cardiac myosin. 
 
Recombinant
baculovirus was obtained for each cDNA construct by the protocols
described by O’Reilly et al. (26). To express a truncated human ven-
tricular myosin fragment, Sf21 cells were coinfected with the recom-
binant viruses expressing truncated 
 
b
 
-MHC, LC1, and LC2 (11, 27).
The cells were harvested 84 h after infection. The expressed human
cardiac myosin was purified as described previously (27).
 
Gel electrophoresis, immunoblot, and ATPase assay. 
 
SDS poly-
acrylamide gel electrophoresis was carried out on a 7.5–20% poly-
acrylamide gradient slab gel. Immunoblots were performed as de-
scribed previously (28) using an anti–human 
 
b
 
-MHC monoclonal
antibody (HMC14) and an anti–human ventricular LC1 antibody
 
(MLM544) (generous gifts from Dr. Katoh, Yamasa Corp., Chiba, Ja-
pan). Nondenaturing gel electrophoresis was performed according to
Persechini et al. (29) in the presence of 2 mM Mg
 
2
 
1
 
-ATP. ATPase ac-
tivity was measured as described previously (30) under conditions de-
scribed in the legend to Table I.
 
In vitro motility assay. 
 
The in vitro motility assay was performed
as described previously (14). Each video frame was digitized at a rate
of five frames/s into a 320 
 
3
 
 240 pixel array by a video grabber card
(Video Blaster; Creative Labs, Milpitas, CA) installed in a personal
computer (Compudyne 614295; CompUSA, Dallas, TX). Actin fila-
ment velocity was calculated from the movement distance and the
elapsed time in successive snapshots.
 
Statistical analysis. 
 
For each myosin, measurements were made on
three different preparations expressed independently. All data are pre-
sented as mean value
 
6
 
SD. Student’s 
 
t
 
 test was used for statistical compar-
ison of mean values. A value of 
 
P
 
 
 
,
 
 0.05 was considered to be significant.
 
Results
 
Expression and purification of human 
 
b
 
 cardiac myosin. 
 
The
produced human 
 
b
 
-MHC contains Met
 
1
 
-Asp
 
1138
 
 with calcu-
Figure 2. Isolation of the human b cardiac 
myosin expressed in insect cells. (A) 7.5–12% 
SDS-polyacrylamide gel electrophoresis of my-
osin fragments. (lane 1) Molecular weight stan-
dard; (lane 2) naturally isolated human cardiac 
myosin; (lane 3) human cardiac HMM; (lane 4) 
truncated human cardiac myosin (wild-type) 
purified from insect cells; (lane 5) Arg249Gln 
mutant myosin; (lane 6) Arg403Gln mutant 
myosin; (lane 7) Arg453Cys mutant myosin; 
(lane 8) Val606Met mutant myosin. (B) Im-
munoblot of human cardiac myosins (wild-
type) using a monoclonal antibody, HMC14, 
which recognizes human b-MHC. (lane 1) 
naturally isolated human cardiac myosin; 
(lane 2) expressed human cardiac myosin. 
(C) Immunoblot of human cardiac myosins 
(wild-type) using a monoclonal antibody, 
MLM544, which recognizes human cardiac 
LC1. (lane 1) Naturally isolated human car-
diac myosin; (lane 2) expressed human car-
diac myosin.
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Figure 3. Nondenaturing gel electrophoresis of cardiac myosin frag-
ments. (lane 1) Human cardiac HMM; (lane 2) truncated cardiac myosin 
expressed in insect cells (wild-type); (lane 3) human cardiac myosin S1.
 
Table I. ATPase Activities of the Expressed Human
Cardiac Myosins
 
K
 
1
 
 EDTA 
ATPase*
Ca
 
2
 
1
 
 
ATPase
 
‡
 
Actin-activated
ATPase activity
 
§
 
Vmax(s
 
2
 
1
 
)
 
K
 
a
 
nmol Pi/mg
per min
nmol Pi/mg
per min (mM)
Wild type 198615 480634 3.3160.30 3064
Arg249Gln 163635 111617 i 1.8860.23 i 3365
Arg403Gln 187611 47765 1.0160.15 i 9867 i
Arg453Cys 74613 i 16168 i 0.7960.11i 3865
Val606Met 168633 451611 2.9860.39 4166
Measurements were made on three independent preparations of each
myosin. All data are presented as mean activity6S.D. *K1 EDTA-AT-
Pase activity was measured in 0.01 mg/ml myosin, 0.1 mM ATP, 10 mM
EDTA, 50 mM Tris-HCl (pH 7.5), 0.6 M KCl at 258C. The reaction was
started by adding ATP and the liberated inorganic phosphate was mea-
sured as described previously (30). ‡Ca21-ATPase activity was measured
in 0.01 mg/ml myosin, 0.1 mM ATP, 2 mM CaCl2, 50 mM Tris-HCl (pH
7.5), and 0.04 M KCl at 258C. §Actin-activated ATPase activity was mea-
sured at 258C in 0.01 mg/ml myosin, 0.1 mM ATP, 50 mM KCl, 20 mM
imidazole-HCl (pH 7.5), 6 mM MgCl2, 0.5 mM EGTA with various con-
centrations of F-actin (0.1–3.2 mg/ml). The maximum hydrolysis rate
(Vmax) and the apparent dissociation constant for actin (Ka) for each
preparation were determined by using a computed nonlinear least-
square curve-fitting program based on a equation, V 5 Vmax/(1 1 Ka/[actin])
(42). iP , 0.05 versus wild type.
lated molecular mass of 130 kD thus containing the entire S1
and most of the S2 portions of myosin. We chose to produce
the heavy chain construct containing both the S1 and S2 portions
of the molecule, because the S2 segment is necessary for a stable
two-headed structure which is important to represent native
motor activity of myosin (27) and because it is technically difficult
to express an entire b-MHC (1,935 amino acids) in insect cells.
After purification, both wild and mutant myosins contained a
130-kD apparent molecular mass heavy chain, a 25-kD LC1,
and a 19-kD LC2 (Fig. 2 A). Approximate stoichiometry of the
three polypeptides was 1:1:1 for both wild and mutant b-MHCs
based upon gel densitometry, indicating that the recombinant
myosins consisted of one heavy chain and one of each class of
light chains as is found in naturally isolated cardiac V3 myosin.
For both wild-type and mutant myosins, z 200 mg of the puri-
fied myosins were obtained from 10 grams of Sf21 cells.
To confirm the authenticity of the expressed proteins,
immunoblot analyses were performed using two kinds of
antibodies recognizing either human b-myosin heavy chain
(HMC14) or human ventricular LC1 (MLM544) (31). The
former antibody recognized the expressed truncated b-MHC
as well as a naturally isolated human ventricular MHC (Fig.
2 B). The latter antibody reacted with both the expressed LC1
and the naturally isolated one (Fig. 2 C) suggesting that the ex-
pressed myosin fragment is the human cardiac b-myosin.
Nondenaturing gel electrophoresis was used to determine
whether the expressed b-MHC forms a double-headed structure
or a single-headed structure. As shown in Fig. 3, the entire
fraction of the expressed myosin migrated at the similar posi-
tion to that of the naturally isolated cardiac heavy meromyosin
(HMM) but much slower than naturally isolated cardiac S1,
suggesting that the expressed b-MHC forms a stable dimer,
i.e., V3 isoform.
ATPase activities of the expressed myosin. The enzymatic
function of the expressed myosins was evaluated by measuring
K1EDTA-activated and Ca21-activated ATPase activities as
well as the actin activated Mg21-ATPase activity. The obtained
values for the wild-type recombinant b-myosin ATPase are
shown in Table I. These values are similar to those measured
for naturally isolated V3 cardiac HMM (32) or S1 (33) indicat-
ing that the expressed b-myosin is properly folded and retains
native enzymatic properties. While the K1EDTA-ATPase
activity as well as Ca21-ATPase activity of the Arg403Gln
and the Val606Met mutant myosins was not significantly
different from those of the wild-type myosin, the Arg249Gln
and Arg453Cys mutants showed a large difference. The
Arg249Gln mutant showed a decreased Ca21-ATPase activity
without significant change in K1EDTA-ATPase activity, while
the Arg453Cys mutation resulted in significant decrease in both
K1EDTA- and Ca21-ATPase activities, suggesting that these
mutations change the conformation of the ATPase active site.
Consistent with these results, the Vmax of actin-activated
ATPase activity was significantly decreased for both Arg249Gln
and Arg453Cys mutants without changing the apparent disso-
ciation constant for actin (Ka). On the other hand, while both
Ca21- and K1EDTA-ATPase activities were unchanged, the
Arg403Gln mutant showed a significantly decreased Vmax
(31% of the wild-type) and a significantly increased Ka (3.3
times higher than that of the wild-type) for the actin activated
ATPase activity suggesting the change in the actin dependent
process of myosin ATPase reaction rather than the direct ef-
fects on the ATPase active site. The ATPase activities of the
Val606Met mutant were not significantly different from those
of the wild-type myosin.
Actin-translocating activity of the expressed myosin frag-
ments. Fig. 4 shows the sliding velocity of actin filaments on the
recombinant human cardiac myosins. More than 90% of actin
filaments moved smoothly and unidirectionally on all myosins.
There was no significant difference between the wild-type and
the mutant myosins in the proportion of the moving actin fila-
ments. The sliding velocity for the wild-type myosin was
1.6460.14 mm/s at 308C. This value is similar to that of natu-
rally isolated V3 cardiac myosin (14–16), further confirming
the authenticity of the expressed myosin. The sliding veloci-
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Figure 4. Sliding velocity of actin filaments on the expressed myosins. 
Actin movement was observed in 30 mM KCl, 5 mM MgCl2, 25 mM 
imidazole-HCl (pH 7.5), 1 mM EGTA, 1% 2-mercaptoethanol, 0.5% 
methylcellulose, 4.5 mg/ml glucose, 216 mg/ml glucose oxidase, 36 
mg/ml catalase, and 2 mM ATP at 308C. Measurements were made on 
three independent preparations of each myosin. 20–30 actin filaments 
were measured to obtain an average velocity for each preparation. 
All values are mean velocities6SD.
ties for the Arg249Gln, Arg403Gln, Arg453Cys, and Val606Met
mutants were 1.0060.11, 0.4460.07, 0.3760.06, and 1.3460.11
mm/s, respectively. All of the mutations resulted in significant
decrease in the actin translocating activity (P , 0.05). The degree
of the decrease in the actin translocating activity was correlated
with the decrease in Vmax of the actin activated ATPase activity.
Particularly, the Arg403Gln and the Arg453Cys mutations most
drastically decreased the velocity by 73 and 77%, respectively.
Discussion
In this study, we succeeded in functionally expressing human
cardiac b-myosins in insect cells (Fig. 5 A). Wild-type myosin
was well purified with similar enzymatic and motor activities to
those of the naturally isolated V3 myosin (14–16, 32, 33), indi-
cating that the recombinant human cardiac myosin mutants
can be used to evaluate the motor activities of the myosin ex-
pressed in patients’ hearts. Another concern for the use of re-
combinant proteins is that mutation might change overall pro-
tein folding and it was reported that substitutions of two amino
acid residues in smooth muscle myosin heavy chain resulted in
a sixfold decrease in isolatable amount of the expressed myo-
sin (34). In this study, however, all of four mutant myosin frag-
ments were well purified with similar yields to that for the
wild-type, indicating that these point mutations do not affect
proper folding of myosin.
All of four point mutations resulted in decrease in myosin
motor function in terms of ATPase and unloaded actin trans-
locating activities. While the force generating capacity of the
recombinant myosins has not been measured, it is plausible
that the power production of the mutant myosin is reduced
since the ATP consumption rate of actomyosin is considerably
decreased by the mutations. Of importance is the finding that
the degree of the dysfunction by the mutation is closely corre-
lated with the prognosis of the disease. According to Watkins
et al. (6), cumulative survival rates at 50-yr-old for Arg249Gln,
Arg403Gln, Arg453Cys, and Val606Met are 79, 36, 34, 94%,
respectively. This coincides well with the extent of the de-
crease in myosin motor activity by the mutation. Arg403Gln
and Arg453Cys, which decrease enzymatic and motor activities
severely (70–80% inhibition), are associated with poor progno-
sis. The Arg249Gln mutation, whose effects on myosin motor
function are intermediate (40–50% inhibition), is associated with
intermediate prognosis. The Val606Met mutation, which affects
myosin function mildly (10–15% inhibition), is associated with
good prognosis. The results suggest that myosin dysfunction
caused by the point mutations is responsible for the pathogenesis
of FHC, although the relative expression level of mutant myosin
in patient’s heart might also contribute to the pathogenesis since
the expression of the mutant myosin is heterogeneous where the
percent mutant expression is unknown from individual to individ-
ual. Furthermore, the results of present study imply that the func-
tional analysis of a certain mutation observed in FHC could pre-
dict the clinical outcome of the kindreds carrying such a mutation,
whose phenotype has not been clinically studied extensively.
The present results also provide fundamentally important
information for understanding the structure/function relation-
ship of myosin. The mutation of Arg249Gln or Arg453Cys not
only resulted in the decrease in actin translocating activity but
also accompanied with a significant reduction of Ca21-ATPase
activity. While the Arg249Gln mutation markedly decreased
Ca21-ATPase activity, the inhibition of K1-ATPase activity
was moderate. This might suggest that Arg249 influences the
coordination of the metal ion of the ATP substrate to myosin
molecule. According to the three-dimensional structure of
skeletal muscle myosin S1 (35–37), Arg249 (corresponding to
Arg251 of skeletal myosin) is in the b-strand six located at the
outer end of the nucleotide binding pocket (Fig. 5 C). This res-
idue is in close proximity of Asp461 (11.6 Å between Arg251 and
Asp463 in skeletal myosin) which participates in the coordina-
tion of the Mg21 ion of the ATP substrate (35, 38, 39) which is
consistent with the observed change in myosin function. On
the other hand, the Arg453Cys mutation decreased both Ca21-
and K1-EDTA ATPase activities to similar extent, suggesting
that the mutation influences either ATP binding or the cataly-
sis of ATP hydrolysis. Arg453 is located at the end of the nucle-
otide binding pocket (37). Although this residue is a little dis-
tal from the residues participated in g-phosphate binding
(z 20 Å), it resides in a loop next to the a-helix containing
Asp461, Ala463, Gly464, and Glu466 (corresponding to Asp454, Ser456,
Gly457, and Glu459 of Dictyostelium discoideum myosin) which
are suggested to participate in the binding of g-phosphate of
ATP (38, 39). One of the residues close to Arg453 is Glu448 (10.8
Å between Arg455 and Asp450 in skeletal myosin) and it would
be plausible that charge interaction between Arg453 and an
acidic residue contributes to position the a-helix containing
the several residues involved in g-phosphate binding.
Different from above mutations, the Arg403Gln mutation
did not change the Ca21- and K1-EDTA ATPase activities sig-
nificantly but only decreased the actin dependent ATPase ac-
Functional Expression of Human Cardiomyopathic Myosin Mutants 2871
tivity. The result suggests that this mutation changes the
ATPase reaction steps involved in the actin dependent process
(40). Consistent with this finding, the apparent dissociation
constant (Ka) was significantly increased for Arg403Gln mu-
tant. The observed functional change is well explained by
structural point of view that Arg403 lies in the loop (Arg403-
Lys413) which forms a close contact with actin (Pro332 to Glu334
of actin molecule) (Fig. 5 B) (36). The Arg403Gln mutation
greatly decreased the actin translocating activity suggesting the
importance of this loop for motor activity of myosin.
Val606 is in a helix-loop-helix motif just at the upstream of
the junction of 50–20 kD subdomains of S1 which contain a
part of actin binding interface of myosin molecule (35, 37). The
effect of Val606Met mutation on myosin motor and enzymatic
activities was mild. On the basis of the structural analysis of
acto-S1 complex (36), there are no indications of the impor-
tance of this segment for actin–myosin interaction, therefore,
the very mild modulation of myosin function by the Val606-
Met mutation would be reasonable, although the mild func-
tional modulation would be partly due to the conserved substi-
tution of the amino acid residue, i.e., Val to Met.
It is still unclear how a missense mutation leads to cardiac
hypertrophy, myocardial fiber disarray, or fatal arrhythmia, al-
though it may be plausible that myosin motor dysfunction con-
stitutes the primary stimulus for the cardiac hypertrophy as
compensation for the reduced contractile function resulting
Figure 5. Locations of the point 
mutations expressed in this 
study. (A) The three-dimen-
sional structure of the chicken 
skeletal myosin S1 (35) showing 
the positions equivalent to the 
point mutations in b cardiac my-
osin; (B) a close-up stereoview 
of the region of the actin binding 
interface. The Arg403-Lys413 loop 
is indicated in a bold line; (C) a 
close-up stereoview of the ATP 
g-phosphate binding pocket. 
The loop containing Glu448, 
Arg453, Asp461, Gly464, and Glu466 
is indicated in a bold line.
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from the dysfunction of the individual cross-bridge. Although
the four mutations tested in this study were different in the de-
gree of the dysfunction of myosin motor, the patients carrying
the mutations on the b-MHC tend to produce cardiac hyper-
trophy to a similar extent of each other (1, 2, 6–9), suggesting
that cardiac hypertrophy is not directly related to the prognosis
of the disease. Consistent with this notion, it was reported that
homozygous transgenic mice carrying the Arg403Gln mutation
were live-born and had normal gross cardiac anatomy but uni-
formly died by day 7 (41). Myocardial hypertrophy itself may
not be the cause of death but deterioration of cardiac myosin
motor function may trigger some process to threaten a life.
In summary, this is the first report which analyzed the ef-
fects of point mutations on the motor function of human b car-
diac myosin in detail. The methodology used in this study en-
ables us to study the structure/function relationship of myosin,
providing clinical implication for the prognosis of the patients
carrying a certain mutation in the b-MHC gene.
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